Many people with chronic lymphocytic leukemia (CLL) seek out information online about foods, vitamins, and supplements to help them fight their disease. But it’s important to speak with a medical professional before trying any new treatment.
For example, a recent study found that high doses of green tea may actually reduce the effectiveness of cancer medications.
CAR NK Cell Therapy
CAR NK cell therapy involves genetically engineered natural killer (NK) cells that recognize tumor antigens using synthetic receptors. The NK cells are then administered in combination with a standard immunotherapy regimen. Unlike CAR T cells, which are manufactured for each patient using an expensive process that requires high levels of donor and patient matching, NK cells can be made off-the-shelf from healthy donor cells or a cellular bank. This makes CAR NK cell therapy more cost-effective, accessible to a larger patient population and less time-intensive for manufacturers.
NK cells are naturally able to infiltrate solid tumors, but they lack the MHC-independent recognition and killing mechanisms of T cells. By enhancing the natural cytotoxic capacity of NK cells with a synthetic CAR, CAR NK cell therapies offer the potential to overcome limitations associated with conventional immunotherapy.
The development of a new generation of CARs has significantly improved the effectiveness and safety of NK cell therapy. The next-generation CARs utilize a dual-CAR design that binds two costimulatory molecules to activate NK cells. This allows the cells to recognize multiple tumor targets and kill them more efficiently. In addition to the enhanced binding, CAR NK cells have a natural MHC-independence that reduces the risk of off-target rejection [5].
Clinical trials of CAR NK cell therapy are ongoing. The treatment has shown promising results for hepatocellular carcinoma and pancreatic cancer, especially when combined with the PD-1 inhibitor pembrolizumab. Several companies are developing scalable CAR NK platforms to increase manufacturing flexibility and reduce costs. These include Fate Therapeutics, Nkarta, GT Biopharma and Century Therapeutics.
The use of iPSCs and umbilical cord blood as alternative sources for NK cell expansion may also help lower production costs. Moreover, advances in gene editing and ex vivo expansion techniques can enhance the efficiency of NK cell production, enabling the generation of more effective CARs and improving their stability. Additionally, the development of allogeneic NK cell production methods could enable a fully standardized off-the-shelf product for patients with advanced cancer. This would eliminate the need for costly lymphodepletion procedures and minimize concerns about graft-versus-host disease (GVHD) and persistence.
Vaccines
Vaccines are widely recognized as one of the greatest medical advances of our time. They have dramatically decreased disease prevalence, saving countless lives and reducing the emotional and financial burden of serious illnesses on families and healthcare systems. Vaccines do this by inducing antigen-specific immune responses able to protect against the diseases they target. However, vaccines also have downstream effects that we are only just beginning to understand.
Among immunocompromised patients, vaccines can induce antibody-mediated immune responses that may enhance host resistance to infection or provide antigen-specific immunity even in the absence of measurable tumor cells. A variety of factors can influence vaccine response in immunocompromised patients, including age, previous vaccination history, and treatment. These variables are largely modifiable, but achieving a robust vaccine response requires careful consideration and timing.
As a result, vaccines are not routinely recommended for patients with immunocompromising conditions. However, this is changing. The recent development of gene editing therapies, such as CAR-T therapy and mRNA-based vaccines, has opened the door to new approaches for generating more effective vaccines that can be used in patients with immune compromise.
Immunocompromised patients are at high risk of serious infectious complications, especially bacterial infections that can be caused by Staphylococcus aureus and encapsulated bacteria such as Streptococcus pneumoniae. These infections can be life-threatening and lead to complications requiring hospitalization, long-term medical care, or death. Vaccines can help reduce the incidence of these infections by inducing specific immunity, especially against encapsulated bacteria, influenza and herpes zoster.
It is important to note that vaccinations must be performed prior to lymphodepleting therapy such as VenO, as it causes profound immunosuppression. This is true of both healthy and malignant white blood cells and results in the loss of memory B-cells, which produce antibodies. After lymphodepletion, the patient must undergo a full revaccination with a large swath of vaccines in order to restore immunity. However, this can be done safely and successfully with mRNA-based vaccines, indicating that vaccination in immunocompromised patients is feasible and should be part of every cancer patient’s regimen. This is particularly important in the setting of fixed-duration VenO, as demonstrated by a recent study showing that vaccination after this form of therapy did not compromise deep remissions or graft versus host disease (GVHD) outcomes [12]. [13] Moreover, mRNA-based vaccines can be administered with other cll alternative therapies such as BTKi and anti-CD20 mAb.
Radiation Therapy
Radiation therapy can cure some cancers on its own, and enhance results when used with surgery or chemotherapy. It can also prevent recurrence by targeting any remaining cancer cells. Advanced technologies like stereotactic body radiation therapy (SBRT) can give you an extremely high dose of radiation in just a few sessions, helping to reduce side effects and speed up treatment time. Radiation therapists are often flexible, working around your schedule and commitments. This can be a relief for people who are already overwhelmed with treatments.
Stem Cell Transplantation
Stem cells are immature blood cells that can develop into specialized cells, such as red blood cells or platelets. These cells have special jobs that help the body fight infection and maintain a healthy blood supply. Stem cell transplants can also be used to replace cells that have been damaged by chemotherapy or radiation treatments for leukemia.
These transplants involve removing stem cells from your own body and then giving them back to you, often along with other types of blood-forming cells. These transplants can be done with your own hematopoietic stem cells (the healthy blood-forming cells in your bone marrow) or with other types of stem cells, such as those from donated umbilical cord blood or a matched donor.
Some of these stem cells are genetically modified to make them better at fighting cancer. For example, doctors may add a receptor that helps these cells stick to leukemia cells, so the immune system can find and destroy them more easily. These modified cells are called CAR NK cells. This therapy is still being tested in people with chronic lymphocytic leukemia, but it is showing promise.
Doctors can get a person’s own hematopoietic stem cell by using a special needle to draw out some fluid marrow from the top part of the sternum (breastbone) or the pelvic bone. This can be done at a hospital or clinic.
The person may have to take medicines that suppress the immune system before getting their own hematopoietic stem or other cells back in the body. They might have to stay in the hospital for several weeks or longer, and they will need to get blood tests often. Medicines can be given to prevent or treat problems that can happen after a transplant, such as rejection of the donor’s stem cells and graft-versus-host disease.
Allogeneic transplant uses stem cells from a matched donor who has the same tissue type as the person getting the treatment. This is a type of stem cell transplant that has been shown to be effective against many kinds of leukemia and lymphomas (cancers derived from white blood cells) and some other conditions.